Theorem Clinical Research?s alliance with Charles River Laboratories will provide nonclinical testing programs in the areas of bioanalysis, immunogenicity, and immunology.
The CRO, Theorem Clinical Research has formed an alliance with the CRO, Charles River Laboratories that will provide clients with an integrated solution from nonclinical testing and analysis through clinical development and registration. The new alliance provides nonclinical testing programs in the areas of bioanalysis, immunogenicity, and immunology to support clinical trials.
Charles River’s research models, preclinical testing capabilities and clinical support services are backed by a bioanalysis portfolio for non-GLP and GLP programs. Laboratories are equipped with instrumentation to measure drug and metabolite concentrations in biological matrices and to provide support for capillary micro- sampling and dried blood spot analysis.
Source: Theorem Clinical Research
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.